Overview

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Desvenlafaxine Succinate